Skip to main content

Closed

ELVN: Enliven Therapeutics, Inc. Stock Analysis | finqOS

Healthcare · Biotechnology

Loading chart data...

Current StateBalance holding

The verdict

Good business

Weak

Revenue growth+0.0% / yr

Operating margin0.0%

ROIC-25.5%

Financially safe

Stretched

Debt / equity0.00×

Interest coverage0.0×

Current ratio40.32×

Enliven Therapeutics, Inc.

ELVNNASDAQ Global Select·USD·Closed

Enliven Therapeutics, Inc.

ELVNNASDAQ·USD·Closed

$54.81

+1.59%

$54.81

+$0.86 (1.59%)

52W Range

98thpctl

Volume

0.48×avg

Mkt Cap

3.92BUSD

P/E

-33.4TTM

Div Yield

–ann

52W Range

98thpctl

Volume

0.48×avg

Market Cap

3.92BUSD

P/E Ratio

-33.4TTM

Div Yield

-ann

Overview Financials Peers Sentiment Analysis Transcripts Holders Company SEC Filings

Overview Financials Peers Sentiment Analysis Transcripts Holders Company SEC Filings